Recurrent small cell lung carcinoma
Clinical trials for Recurrent small cell lung carcinoma explained in plain language.
Never miss a new study
Get alerted when new Recurrent small cell lung carcinoma trials appear
Sign up with your email to follow new studies for Recurrent small cell lung carcinoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo attack on stubborn cancers shows promise in early trial
Disease control CompletedThis phase II trial tests whether combining the immunotherapy drug nivolumab with the chemotherapy drug temozolomide can shrink tumors in people with small-cell lung cancer that has returned or not responded to treatment, or advanced neuroendocrine tumors. About 55 participants w…
Matched conditions: RECURRENT SMALL CELL LUNG CARCINOMA
Phase 2 • Sponsor: Dwight Owen • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Lung cancer trial tests two new combo therapies against tough disease
Disease control CompletedThis phase II trial studied 168 people with extensive-stage small cell lung cancer. Researchers added either vismodegib or cixutumumab to standard chemotherapy (cisplatin and etoposide) to see if these combinations worked better than chemo alone. The goal was to slow cancer growt…
Matched conditions: RECURRENT SMALL CELL LUNG CARCINOMA
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Old arthritis drug paired with immune suppressant shows promise against tough lung cancers
Disease control CompletedThis study tested two drugs—auranofin (originally for arthritis) and sirolimus (an immune suppressant)—in 29 people with advanced or recurrent lung cancer who had no standard options left. The goal was to find the safest dose and see if the combination could slow cancer growth. T…
Matched conditions: RECURRENT SMALL CELL LUNG CARCINOMA
Phase 1/2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 26, 2026 13:58 UTC